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Highlights 
 Radiotherapy aims at tumor control with the least damage to healthy tissue. 
 The toxicity of the treatment may be acute and / or chronic. 
 Radiosensitivity is a multifactorial and polygenic trait. 
 SNPs in ATM, IL6 and TNF are key in clinical radiosensitivity. 
 
ABSTRACT  
Although oncological therapies have improved in the last decades, breast cancer (BC) remains a 
serious health problem worldwide. Radiotherapy (RT) is one of the most frequently used 
treatments for cancer aimed at eliminating tumor cells. However, it can also alter the surrounding 
normal tissue, especially the skin, and patient reactions may vary as a result of extrinsic and 
intrinsic factors. We evaluated the association of gene polymorphisms ATM Asp1853Asn, IL-6 
G-174C and TNF-α G-308A involved in central phenotype pathways and development of 
individual radiosensitivity in BC patients with an exacerbated response to RT. Although 
univariate analysis results did not show a significant association with this trait, the interaction 
analysis between polymorphisms showed an increased risk of patients presenting wild-type TNF-
α G-308A genotype and mutant IL-6 G-174C genotype, and heterozygous TNF-α G-308A 
genotype and heterozygous IL-6G-174C genotype. On the other hand, our results showed that 
breast size and patient age influenced the determination of RT-associated effects. Considering 
that the trait is multifactorial, other significant elements for the determination of individual 
radiosensitivity should be considered, together with the establishment of specific polymorphic 
variants. 
 
Keywords: Radiotherapy; Breast cancer; Radiosensitivity; Polymorphisms 
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1. Introduction 
Female breast cancer (BC) mortality and morbidity is very high worldwide and is expected to 
rise in the next decades, with approximately 115,881 new cases and 32,014 deaths in 2012 in 
South America [1,2]. In this context, treatment optimization is of great importance. Although 
different therapeutic tools such as surgery, chemotherapy and hormone therapy are available, 
radiotherapy (RT) has gained relevance in cancer treatment due to technological and informatics 
advances, thus becoming a mainstay for most patients diagnosed with this disease [3,4]. RT is 
always used after conservative surgery and occasionally after mastectomy to eliminate possible 
residual tumor cells. Although RT is aimed at eliminating tumor cells, healthy cells in the field 
of irradiation can also be injured, and while normal tissues are able to repair, repeated exposure 
to radiation generates an imbalance between damage and tissue recovery [5].  
Normal tissue injury can be both acute and late. The former develops during treatment and is 
usually reversible, whereas the latter can occur from six months after RT and even several years 
later, and can be permanent [6,7]. Skin injuries may include mild to severe dermatitis, ulceration, 
fibrosis, telangiectasias and even radio-induced cancers [8]. Despite the use of similar protocols, 
radiotoxicity effects vary among patients, which cannot be explained only by extrinsic factors 
but could also be attributed to underlying genetic differences [9]. The main causal elements of 
individual radiosensitivity are related to physics (radiation dose, dose rate, dosimetry, dose 
inhomogeneity and volume of treatment), to the interaction with other therapies such as surgery, 
chemotherapy and hormone therapy, and to the patient condition (age, haemoglobin levels, 
smoking, co- morbidities such as diabetes and vascular diseases). On the other hand, intrinsic 
factors are concerned with individual radiosensitivity as a multifactorial and polygenic trait, 
involving DNA repair pathway genes, oxidative stress, endothelial damage and inflammatory 
response, among others [10,11]. In this context, considering the importance of radiogenomics as 
a potential tool in the individual radiosensitivity determination and the efforts that are being 
developed in different laboratories worldwide, for the validation and/or determination of the 
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different polymorphisms that are part of this feature is interesting the study of particular 
populations never before analyzed, such as Argentina. 
Considering the central effects of ionizing radiation, ATM protein product plays a key role in 
the detection and repair of radio-induced double-strand breaks (DSBs) mediating this response 
by phosphorylating numerous substrates involved in specific signalling pathways [12]. 
Epidemiological evidence suggests that ATM functional genetic variants may have an impact on 
the risk of presenting RT-induced side effects [13]. However, the holistic approach of modern 
radiobiology complements this target theory, arguing that the pathogenesis of normal tissue is 
centralized in the inability to repair and recover cells because the microenvironment perpetuates 
chronic deterioration. This environment is established through feedback of free radicals, cytokine 
and chemokine cascades that provide a progressive inflammatory response over time. Among 
these elements, interleukin 1/6 (IL1, IL-6) and tumour necrosis factor alpha (TNF-α) are the 
most frequently studied [14]. In this way, ionizing radiation is able to stimulate the immune 
system and promote the bystander effect, thus amplifying the effect of RT [15]. Accordingly, 
apical kinases such as ATM and pro-inflammatory cytokines play a leading role in the 
establishment of radiotoxicity as a phenotype. Therefore, the determination of single nucleotide 
polymorphisms (SNPs) in these genes could be particularly interesting for their relative 
contribution to radiogenomics, which attempts to establish the influence of genetic variation on 
the response to radiation.  
The aim of this study was to evaluate the association between risk of severe skin reactions in 
BC patients and ATM G1853A, TNF-α G-308A and IL6 G-174C polymorphisms. These 
elements would contribute to determine the genetic profile of response to RT as a tool for 
preventing radiotoxicity and optimizing treatment in the field of precision medicine [16].  
 
2. Materials and methods 
2.1. Subjects 
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Following surgery, BC patients who underwent RT (n=125) were recruited during 2012-2016 
at the Oncology Integrated Center (CIO-La Plata, Terapia Radiante SA), the main RT center in 
La Plata, one of the most demographically important areas of Argentina. Of these, 14 individuals 
who developed severe radiodermatitis (grades 3 and 4) according to the RTOG (Radiation 
Therapy Oncology Group) score were selected and 14 other individuals were used as controls 
(grade 0). Grade 3 is characterized by confluent moist desquamation and severe edema, while 
grade 4 presents with haemorrhages, ulceration and necrosis [17]. The occurrence and severity of 
these reactions were determined during and after treatment, taking into account the highest 
degree of toxicity achieved.  
Before treatment, 5 mL of peripheral blood was extracted in sterile tubes containing EDTA.  
In some cases, oral swabs were also collected. Patient data (age, ethnicity, alcohol consumption, 
smoking, co-morbidities, body mass index and breast size) were recorded through an interview. 
All patients were treated with conventional 3D external beam therapy (total dose 
administered, 50-50.4 Gy, delivered for 5 weeks in daily fractions of 1.8-2 Gy). 
Each patient was informed about the study protocol, both verbally and in writing. Only 
patients who gave their informed consent were included in the study, in accordance with the 
Declaration of Helsinki. 
 
2.2. DNA isolation and polymorphism genotyping  
ATM G1853A (rs1801516), TNF-α G-308A (rs1800629) and IL6 G-174C (rs1800795) 
polymorphisms were analyzed by pyrosequencing. Genomic DNA was isolated from peripheral 
blood and oral mucosa samples, according to a protocol previously reported [11]. DNA quality 
was evaluated by spectrophotometry (Nanovue, GE Heathcare, Buckinghamshire, UK). The 
target sequence containing the polymorphic site was amplified by polymerase chain reaction 
(PCR) in which one of the primers was biotinylated. PCR was performed in a total volume of 50 
µL containing ~100 ng genomic DNA, 0.2 mM dNTP mixture, 1-2 mM Cl2Mg, 1.25 U Taq 
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DNA polymerase (Genbiotech, Buenos Aires, Argentina) and 0.5 pmol/µL primer pairs (Table 
1). Reaction conditions were as follows: initial denaturation at 94 °C for 3 min and 35 cycles at 
94 °C for 30 sec, annealing at 55-57 °C for 30 sec, elongation at 72 °C for 30 sec and final 
elongation at 72 °C for 2 min. After amplification, 20 µL biotinylated amplicons were taken to 
generate a single-strand template by removing the non-biotinylated strand on streptavidin-coated 
beads (matrix). The DNA template bound to the affinity matrix was separated by denaturation in 
NaOH and used for the following synthesis of a short-strand DNA (10-15 bases) adjacent to the 
SNP site. The specific sequence primers are also reported in Table 1. Polymorphisms were 
analyzed using pyrosequencing technology (Pyrosequencing AB, Uppsala, Sweden) according to 
a previously published method [18]. 
 
2.3. Statistical analysis 
Allele compliance with Hardy-Weinberg equilibrium and differences in clinical factors 
between cases and controls were assessed using chi-square test (p-value <0.05). Odds ratios 
(OR) and 95% confidence intervals (CI) were calculated considering the genotypic dominant 
model of inheritance. Statistical analyses were performed using IBM SPSS v.19 (IBM Co., 
Armonk, NY). The interactions of the genes analyzed with the development of skin radio-
induced toxicity were detected by the multifactor dimensionality reduction (MDR) software 
(version 3.0.2) [19]. 
 
3. Results 
The sample analyzed in this study corresponds to 11.3% of the total patients recruited 
(patients with severe skin effects grade 3 and 4; mean age, 58 years).  
Univariate analysis results showed that patients with severe radiodermatitis differed from 
controls regarding advanced age in relation to the median value (>59 years) (OR= 6.6, p= 0.02) 
and breast size (OR=10.4; p=0.04), since patients with large and medium-sized breasts had a 
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higher risk of developing severe skin reactions (Figure 1). In addition, the analysis performed 
taking into account other factors such as hypertension, diabetes, alcohol consumption, smoking 
and body mass index showed no significant differences between cases and controls. 
On the other hand, sample genotyping was successfully performed using pyrosequencing, a 
simple technique for accurate and consistent analysis of large numbers of short- to medium-
length DNA sequences. Pyrograms of each genotype corresponding to the polymorphisms 
studied are shown in Figure 2. The genotype distribution of patients included in the analysis is 
shown in Table 2. All of them were in Hardy-Weinberg equilibrium (p >0.05), and the 
homozygous minor alleles of ATM and TNF-α were absent in the population. The frequencies of 
variant alleles in the whole set of BC patients were 0.16 (ATM Asp1853Asn), 0.04 (TNF-α G-
308A) and 0.45 (IL6 G-174C). After the statistical analysis of association of ATM Asp1853Asn, 
TNF-α G-308A and IL6 G-174C polymorphisms with development of grade 3 and 4 
radiodermatitis, no significant differences were observed in OR increase/decrease (p ˂ 0.05; 
Table 2). Interaction analysis results of the association between severe radiotoxicity and TNF-α 
G-308A and IL6 G-174C polymorphisms were significant, presenting a CVC of 10/10 and a 
balanced accuracy of 0.6382. Thus, we could identify two risk groups: patients with 
heterozygous TNF-α G-308A genotype and heterozygous IL6 G-174C genotype, and wild TNF-
α- G-308A genotype and mutant IL6 G-174C genotype (Figure 3). 
 
4. Discussion and conclusions 
Initially, individual radiosensitivity was studied through cytogenetic and cellular tests such 
as the comet assay, G2 and cell survival and their combination [20,21,22,23]. However, none of 
these methods has been validated in a clinical setting. Currently, interest is focused on the 
investigation of genetic variation, due to advances in genetics, molecular biology and 
bioinformatics. It is proposed that radiosensitivity studies should be based on the genotype of the 
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patients, instead of phenotypic aspects, such as cellular radiosensitivity, thus giving rise to 
radiogenomics. 
This study is part of a major project in which polymorphisms are studied in genes involved 
in various radio-induced routes, such as oxidative stress, DNA repair, cell cycle control and other 
pro-inflammatory cytokines.  
Considering that ATM protein products are central in DNA damage response (DDR), we 
assessed their relative involvement and verified their role as risk alleles in establishing the 
toxicity to normal tissue triggered by RT. ATM serine/threonine kinase itself plays a crucial role 
as a sensor in the activation of cell cycle checkpoints in response to RT-induced DNA DSBs 
[24]. Genetic variants can lead to structural and functional protein changes, with the consequent 
defect in the ability of cells to sense and repair DNA damage [25]. In this way, ATM 
Asp1853Asn (rs1801516) should be evaluated as a common missense variant located in exon 39, 
and the G to A change leads to the substitution of asparagine for aspartic acid at amino acid 
position 1853. Although our results are in agreement with the meta-analysis of Su et al. [13], 
who showed that ATM Asp1853Asn polymorphism does not contribute to the development of 
RT-induced side-effects, this variant was neither present in patients with radiotoxicity nor in 
asymptomatic patients of our study population. Results with respect to this SNP are controversial 
since other studies suggest that the 1853Asn allele contributes to the risk of developing severe 
effects in normal tissue in BC and prostate patients undergoing RT [26]. 
On the other hand, we also evaluated essential elements of the inflammatory response in the 
establishment of individual radiosensitivity. Further from causing a direct damage to cells, 
radiation into the skin also induces inflammation, releasing cytokines such as IL-6, IL1, IL-8 and 
TNF-α that are able to stimulate the immune system and promote local bystander effects [27]. 
Interleukin 6 (IL-6) has a regulatory role in cell proliferation, differentiation and the balance 
between pro-inflammatory and anti-inflammatory pathways. IL-6 promoter contains several 
SNPs, of which -174G> C is the most widely studied for its influence on various cancers [27]. 
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On the other hand, Siva et al. [28] mention that the activation of macrophages by radiation 
induces the production of IL-6 that mediates acute and late tissue response. However, in the 
present study, the univariate analysis did not corroborate their participation in these effects in 
normal tissue. 
TNF-α G-308A (rs1800629) polymorphism is in the promoter lying 308bp upstream of the 
transcription start site. Whereas Talbot et al. [29] found association between TNF-α rs1800629 
and breast radiotoxicity in a study of 340 individuals, our results showed no association between 
radiosensitivity and the polymorphism analyzed. This could be explained by the fact that the G 
and A alleles did not significantly alter TNF-α expression, as reported by Mekinian et al. [30]. 
Regarding the interaction between IL-6 G-174C and TNF-α G-308A polymorphisms, the 
effect of IL-6 may be more important when interacting with TNF-α, as reported by Schindler et 
al. [31]. These authors mention that the expression of TNF-α is influenced by IL-6. In this way, 
the wild variants of IL-6 would allow the suppression of TNF-α transcription and therefore a 
lesser contribution to radiotoxicity, whereas the polymorphism detected in IL-6 would not exert 
this effect and activate the transcription of necrosis factor, exacerbating the risk of presenting 
acute effects. 
The analyzed genes play a hierarchical role in different routes of response to radiotherapy; 
however, their impact on the establishment of RT-induced toxicity has not been proven. These 
data should be confirmed with a larger number of samples. The complexity of the underlying 
genetic model proposes that increased radiosensitivity could be conferred from a single rare 
mutation with a large effect to a combination of multiple common variants jointly [8,32].  
Considering other factors influencing this phenotype, our results suggest that older patients 
and larger breasts have an increased risk of radiodermitis. There is conflicting evidence of an 
effect of age on the prevalence and severity of radiotoxicity [33,34]. In this study, we found that 
patients older than 59 years were at higher risk for acute effects. Advanced age in adults is 
generally associated with a decreased normal tissue tolerance. The progressive reduction of the 
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functional reserve due to depletion of tissue stem cells could increase normal tissue damage and 
the risk of complications [35]. On the other hand, larger breast volumes require larger doses to 
be applied to the skin to achieve the desired dose in tissue and deeper structures [34]. Large areas 
of skin and folds of the breast are exposed to radiation by increasing breast volume. In agreement 
with Back et al. [36], the present results corroborate that patients with medium and large breasts 
show a more severe skin reaction. Besides, although factors such as BMI, tobacco, alcohol, 
concomitant diseases (diabetes, hypertension) have been analyzed, these were not significant for 
severe acute skin reactions. This could be due to the small number of patients presenting these 
characteristics and to the sample size. In addition, there is no solid evidence that these elements, 
except BMI, represent risk factors for acute clinical radiosensitivity. 
According to the above mentioned and the multifactorial nature of the trait, different elements 
such as breast size and age of the patients should be considered together with the polygenic 
component. Although radiogenomics has led to a better understanding of the pathways involved 
in the determination of individual radiosensitivity for a few years, the involvement of the tissue 
microenvironment forces the evaluation of this response to a broader and unclarified level of 
complexity. 
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Table 1 
 Sequences of the forward, reverse and internal primers for pyrosequencing.                                                                 
Gene SNP Primer Sequence (5´- 3´) 
Fragment 
Size 
ATM G1853A 
F- PCR 
R- PCR 
Sequencing 
F-
GTCAGACTGTACTTCCATACTT 
R- TGAAAAATCCCTGAACAT 
S- TTCATGATATTTTACTCCAA 
99 bp 
TNF-α G -308A 
F- PCR  
R- PCR 
Sequencing 
F- GGAGGCAATAGGTTTTGA 
R- GCCACTGACTGATTTGTG 
S- GGCTGAACCCCGTCC 
74 bp 
IL-6 G-174C 
F- PCR 
R- PCR 
Sequencing 
F- TTCCCCCTAGTTGTGTCT 
R- GGAAAATCCCACATTTGA 
S- CCCTAGTTGTGTCTTGC 
132 bp 
biotinylated primer 
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Table 2 
Association between ATM G1853A, TNF-α G-308A and IL-6 G-174C SNPs and manifestation 
of radiodermatitis throughout the treatment. 
Gene Genotype n (%) 
Radiodermatitis 
OR 95% CI p 
Grade 0  Grade 3-4 
TNF-α 
G-308A 
CC 26 (93) 14 12 1 
  
CT 2 (7) 0 2 5.83 0.5-133.80 0.22 
TT 0 0 0 
   
C 27 (96) 14 13 1 
  
T 1 (4) 0 1 3.23 0.12-85.59 0.46 
IL-6 
G-174C 
GG  6 (21) 2 4 1 
  
GC 19 (68) 10 9 2.16 0.17-27.07 0.54 
CC 3 (11) 2 1 
   
G 15,5 (55) 7 8,5 1 
  
C 12,5 (45) 7 5,5 1.54 0.14-2.89 0.57 
ATM 
G1853A 
GG 19 (68) 9 10 1 
  
GA 9 (32) 5 4 0.72 0.14-3.54 0.68 
AA 0 0 0 
   
G 23.5 (84) 11.5 12 1 
  
A 4.5 (16) 2.5 2 0.76 0.10-5.82 0.79 
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Figure 1 
Comparison between patients who developed grade 3 and 4 severe radiodermatitis and 
asymptomatic patients. A. In relation to age, it is observed that those patients with a median age 
(˃59 y) are more at risk of developing severe dermitis. B. Regarding breast size, it has been 
observed that patients with medium and large breasts are more at risk of presenting radiodermitis 
than patients with small breasts.* represents p ˂0.005. 
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Figure 2 
Pyrograms obtained after genotyping ATM G1853A, TNF-α G-308A and IL-6 G-174C 
polymorphisms. The yellow area shows the peaks that represents the resulting genotypes. The 
theoretical histogram is shown below each one. 
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Figure 3 
Interaction analyses with MDR. A. Interaction model for TNF-α G−308A and IL-6 G−174C 
polymorphisms when comparing the groups with severe radiotoxicity (left bars) and controls  
(right bars), which are illustrated for each multilocus genotype combinations. Light gray cells are 
labelled as low risk and dark gray cells are labelled as high risk. White cells indicate that there 
are no individuals with combinations of these genotypes. B. Entropy decomposition. The effect 
provided by TNF-α G−308A individually is higher than the effect resulting from the interaction 
between these two genes in establishing radiotoxicity risk. 
 
 
 
 
AC
CE
PT
ED
 M
AN
US
CR
IPT
